Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor

Eur Neurol. 1976;14(5):321-8. doi: 10.1159/000114756.


Since L-dopa in combination with a decarboxylase inhibitor is currently the most effective therapy available for treatment of Parkinson's disease, the authors compare the actual causes of death in a large series of treated Parkinson patients with a normal population and with previous studies. This investigation shows that the mortality of correctly treated Parkinson patients lies within the range of the expected mortality of a group of a normal population comparable in age and sex. The risk of death for a Parkinson patient is therefore no longer higher than for the normal population.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Benserazide / administration & dosage
  • Benserazide / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydrazines / therapeutic use*
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / mortality*
  • Retrospective Studies
  • Switzerland


  • Hydrazines
  • Levodopa
  • Benserazide